Prognostic role of sarcopenia in metastatic colorectal cancer patients during first-line chemotherapy: A retrospective study

Table 1 Correlation between sarcopenia, age, body mass index, stage at diagnosis, neutrophil/lymphocyte ratio, toxicity and response to treatment, n (%)

		Sarcopenia		P value
	Total	No	Yes
Age				1
≥ 70 yr	20 (35.7)	15 (35.7)	5 (35.7)
BMI (kg/m2)				0.728
18.5-24.9	21 (37.5)	15 (35.7)	6 (42.9)
25-30	22 (39.3)	16 (38.1)	6 (42.9)
> 30	13 (23.2)	11 (26.2)	2 (14.3)
Stage at diagnosis				0.355
TNM II/III3	23 (41.1)	19 (45.2)	4 (28.6)
TNM IV	33 (58.9)	23 (54.8)	10 (71.4)
NLR				0.751
≥ 3	18 (32.1)	13 (31)	5 (35.7)
Toxicity during the first 4 chemotherapy cycles
At least one dose reduction	17 (30.4)	13 (31)	4 (28.6)	1
Diarrhea G ≥ 2	10 (17.9)	8 (19)	2 (14.3)	1
Neutropenia G ≥ 3/4	11 (19.6)	8 (19)	3 (21.4)	1
Response to treatment				0.221
Partial/complete response	27 (48.2)	18 (42.9)	9 (64.3)

BMI: Body mass index; NLR: Neutrophil/lymphocyte ratio.